(Q39998770)

16 September 2017

Suppression of tumorigenesis by human mesenchymal stem cells in a hepatoma model (English)

1 reference

16 September 2017

hepatocellular carcinoma

1 reference

Ling Qiao

1

1 reference

16 September 2017

Zhili Xu

2

1 reference

16 September 2017

Tiejun Zhao

3

1 reference

16 September 2017

Zhigang Zhao

4

1 reference

16 September 2017

Mingxia Shi

5

1 reference

16 September 2017

Robert C Zhao

6

1 reference

16 September 2017

Lihong Ye

7

1 reference

16 September 2017

Xiaodong Zhang

8

1 reference

16 September 2017

1 April 2008

1 reference

16 September 2017

1 reference

16 September 2017

18

1 reference

16 September 2017

500-507

1 reference

16 September 2017

4

1 reference

https://scigraph.springernature.com/pub.10.1038/cr.2008.40

16 September 2017

0 references

cites work

Mesenchymal stem cells and their potential as cardiac therapeutics

1 reference

https://api.crossref.org/works/10.1038%2FCR.2008.40

Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi's sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCR.2008.40

Differential gene expression associated with migration of mesenchymal stem cells to conditioned medium from tumor cells or bone marrow cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCR.2008.40

Regression of an unresectable pancreatic tumor following nonmyeloablative allogeneic peripheral-blood stem-cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCR.2008.40

Present results and perspectives of allogeneic non-myeloablative hematopoietic stem cell transplantation for treatment of human solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCR.2008.40

Allogeneic hematopoietic stem cell transplantation: state of the art and new perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCR.2008.40

Mesenchymal stem cells (MSC) as therapeutic cytoreagents for gene therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCR.2008.40

Interleukin-23-expressing bone marrow-derived neural stem-like cells exhibit antitumor activity against intracranial glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCR.2008.40

The Wnt signaling receptor Lrp5 is required for mammary ductal stem cell activity and Wnt1-induced tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCR.2008.40

Wnt signalling in stem cells and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCR.2008.40

Stem cells, cancer, and cancer stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCR.2008.40

Wnt signaling: is the party in the nucleus?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCR.2008.40

Notch signalling regulates stem cell numbers in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCR.2008.40

NOTCH signaling as a novel cancer therapeutic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCR.2008.40

APC dosage effects in tumorigenesis and stem cell differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCR.2008.40

Up-regulation of Wnt-1 and beta-catenin production in patients with advanced metastatic prostate carcinoma: potential pathogenetic and prognostic implications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCR.2008.40

WNT and beta-catenin signalling: diseases and therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCR.2008.40

Expression profiling and functional analysis of wnt signaling mechanisms in mesenchymal stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCR.2008.40

The Wnt signaling inhibitor dickkopf-1 is required for reentry into the cell cycle of human adult stem cells from bone marrow

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCR.2008.40

Wnt signaling regulates the invasion capacity of human mesenchymal stem cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCR.2008.40

Wnt/beta-catenin signaling inhibits death receptor-mediated apoptosis and promotes invasive growth of HNSCC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCR.2008.40

Regulated subset of G1 growth-control genes in response to derepression by the Wnt pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCR.2008.40

Influence of prostaglandin A2 on Bax, Bcl-2 and PCNA expression in MCF-7 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCR.2008.40

Rapid loss of intestinal crypts upon conditional deletion of the Wnt/Tcf-4 target gene c-Myc

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCR.2008.40

Establishment and properties of fetal dermis-derived mesenchymal stem cell lines: plasticity in vitro and hematopoietic protection in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCR.2008.40

CARP is a novel caspase recruitment domain containing pro-apoptotic protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCR.2008.40

One strategy for cell and gene therapy: harnessing the power of adult stem cells to repair tissues.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCR.2008.40

Monitoring S phase progression globally and locally using BrdU incorporation in TK(+) yeast strains.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCR.2008.40

Close apposition of dynorphin-positive nerve fibres to lymphocytes in the liver suggests opioidergic neuroimmunomodulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCR.2008.40

[Mesenchymal stem cells from bone marrow. Phenotype, aspects of biology, and clinical perspectives]

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCR.2008.40

7 January 2021

Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas.

1 reference

https://api.crossref.org/works/10.1038%2FCR.2008.40

7 January 2021

Treatment with stem cell differentiation stage factors of intermediate-advanced hepatocellular carcinoma: an open randomized clinical trial

1 reference

https://api.crossref.org/works/10.1038%2FCR.2008.40

7 January 2021

The in vitro migration capacity of human bone marrow mesenchymal stem cells: comparison of chemokine and growth factor chemotactic activities

1 reference

https://api.crossref.org/works/10.1038%2FCR.2008.40

7 January 2021

Mesenchymal Stem Cells: Potential Precursors for Tumor Stroma and Targeted-Delivery Vehicles for Anticancer Agents

1 reference

https://api.crossref.org/works/10.1038%2FCR.2008.40

7 January 2021

Variations of components of the plasminogen activation system with the cell cycle in benign prostate tissue and prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FCR.2008.40

7 January 2021

Identifiers

DOI

10.1038/CR.2008.40

1 reference

Dimensions Publication ID

16 September 2017

0 references

1 reference